Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
Briggs E, Kamal MA, Kosloski MP, Linsmeier I, Jusko N, Dolphin N, Chittenden J, Simpson EL, Paller AS, Siegfried EC, Shumel B, Levit NA, Bansal A, Davis JD, Chapel S, Smith DE, Huniti N. Briggs E, et al. Among authors: shumel b. Pharm Res. 2023 Nov;40(11):2653-2666. doi: 10.1007/s11095-023-03616-8. Epub 2023 Dec 11. Pharm Res. 2023. PMID: 38082089 Free PMC article.
Disease Burden and Unmet Need in Eosinophilic Esophagitis.
Bredenoord AJ, Patel K, Schoepfer AM, Dellon ES, Chehade M, Aceves SS, Spergel JM, Shumel B, Deniz Y, Rowe PJ, Jacob-Nara JA. Bredenoord AJ, et al. Among authors: shumel b. Am J Gastroenterol. 2022 Aug 1;117(8):1231-1241. doi: 10.14309/ajg.0000000000001777. Epub 2022 Apr 13. Am J Gastroenterol. 2022. PMID: 35417421 Review.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A. Dewey FE, et al. Among authors: shumel b. N Engl J Med. 2017 Jul 20;377(3):211-221. doi: 10.1056/NEJMoa1612790. Epub 2017 May 24. N Engl J Med. 2017. PMID: 28538136 Free PMC article. Clinical Trial.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Blauvelt A, et al. Among authors: shumel b. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. Lancet. 2017. PMID: 28478972 Clinical Trial.
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R. Blauvelt A, et al. Among authors: shumel b. J Am Acad Dermatol. 2019 Jan;80(1):158-167.e1. doi: 10.1016/j.jaad.2018.07.048. Epub 2018 Aug 6. J Am Acad Dermatol. 2019. PMID: 30092324 Free article. Clinical Trial.
Conjunctivitis in dupilumab clinical trials.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Akinlade B, et al. Among authors: shumel b. Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Wollenberg A, et al. Among authors: shumel b. Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1. Br J Dermatol. 2020. PMID: 31407311 Free PMC article.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, Weisman J, Wollenberg A, Chen Z, Davis JD, Li M, Eckert L, Gadkari A, Shumel B, Rossi AB, Graham NM, Ardeleanu M. Alexis AF, et al. Among authors: shumel b. J Drugs Dermatol. 2019 Aug 1;18(8):804-813. J Drugs Dermatol. 2019. PMID: 31424712 Clinical Trial.
50 results